非因子治疗时代的凝血因子VIII耐受性:免疫学视角与文献系统综述
重度A型血友病患者中约30%儿童接受凝血因子VIII浓缩物后产生抑制物,其余70%未产生可检测抗体,提示可能已形成对凝血因子VIII的耐受。非因子预防治疗使凝血因子VIII暴露减少至每年仅偶发治疗时刻,其对耐受性的影响目前未知。本文从临床、免疫学和流行病学角度综述凝血因子VIII耐受性,并提供减少暴露对耐受性影响的前瞻性观点。
要点
- 重度A型血友病儿童约30%接受凝血因子VIII浓缩物后产生抑制物,70%未产生可检测抗体。
- 非因子预防治疗使凝血因子VIII暴露减少至偶发治疗时刻,可能长达一年或更久不暴露。
- 减少凝血因子VIII暴露对耐受性的影响目前未知,本文提供免疫学与流行病学视角的展望。
核心结论
- 非因子治疗使重度A型血友病患者凝血因子VIII暴露显著减少,其对凝血因子VIII耐受性的影响目前未知,本文提供临床、免疫学和流行病学视角的展望。
研究设计与样本
- 本文为综述,结合文献系统综述,从临床、免疫学和流行病学角度讨论凝血因子VIII耐受性。
主要发现
- 约30%的重度A型血友病儿童接受凝血因子VIII浓缩物后产生中和性抗凝血因子VIII抗体(抑制物)。
- 其余70%儿童未产生可检测的抗体反应,提示可能已形成对凝血因子VIII的耐受。
- 非因子预防治疗在预防出血方面非常有效,患者可能长达一年或更久不暴露于缺陷的凝血因子VIII蛋白。
临床怎么用
- 非因子预防治疗日益增多,凝血因子VIII浓缩物给药限于出血治疗或围手术期止血。
- 既往重度血友病患者频繁暴露于缺陷抗原,如今暴露减少至偶发治疗时刻。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Persons with hemophilia A lack clotting factor (F)VIII (FVIII) due to a genetic mutation in the F8 gene. The administration of FVIII concentrate leads to the development of neutralizing anti-FVIII antibodies (inhibitors) in about 30% of children with severe hemophilia A. The other 70% of children do not mount a detectable antibody response, suggesting that they may have developed tolerance toward FVIII. Our knowledge on the underlying immunologic mechanisms that determine formation of inhibitors or apparent tolerance to FVIII is limited. Up to recently, FVIII concentrates were regularly used as prophylaxis. In the last years, nonfactor therapy for prophylaxis is increasingly used, in which case FVIII concentrate administration is limited to treatment for bleeding or perioperative hemostasis. As nonfactor therapy is very effective in the prevention of bleeds, patients may not be exposed to the deficient FVIII protein for periods up to a year or longer. Thus, while in the past persons with severe hemophilia were frequently exposed to the deficient antigen, exposure is now reduced to incidental treatment moments. It is currently not known how this will affect the tolerance for FVIII. In this review, we will discuss tolerance to FVIII from a clinical, immunologic, and epidemiologic perspective. We aimed to provide an outlook on the effect of reduced FVIII exposure on tolerance for FVIII in persons with hemophilia A.
引用
- van Stam LE, Lacroix-Desmazes S, Fijnvandraat K, et al. Tolerance to factor VIII in the era of nonfactor therapies: immunologic perspectives and a systematic review of the literature. J Thromb Haemost. 2025. PMID: 39800259. doi:10.1016/j.jtha.2024.12.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。